Effect ofLactobacillus gasseriBNR17 on Overweight and Obese Adults: A Randomized, Double-Blind Clinical Trial

Abstract

BackgroundLactobacillus gasseri BNR17 is a type of probiotic strain isolated from human breast milk. A study was reported regarding the fact that BNR17 was an inhibitor of obesity and diabetic activities in the human body through previous animal experiments. This study was furthered to investigate the effect of BNR17, a probiotic strain isolated from human breast milk, on obese and overweight adults.MethodsSixty-two obese volunteers aged 19 to 60 with body mass index ≥ 23 kg/m2 and fasting blood sugar ≥ 100 mg/dL participated in a placebo controlled, randomized, and double-blind trial. For 12 weeks, 57 participants were given either placebo or BNR17 and were tested by measuring body fat, body weight, various biochemical parameters, vital signs, and computed tomography at the start of the study and at weeks 4, 8, and 12. The subjects assumed usual daily activities without having to make behavioral or dietary modifications during the course of the study.ResultsAt the 12th week, a slight reduction in body weight was noted in the BNR17 group, but there were no significant weight changes between groups. Decrease of waist and hip circumferences in the BNR17 group was more pronounced than those in the placebo group. The two groups had no special or severe adverse reactions.ConclusionDespite there being no change in behavior or diet, administration of only the supplement of BNR17 reduced weight and waist and hip circumference. However, there were no significant differences between the two groups. These findings warrant a subsequent longer-term prospective clinical investigation with a large population.

Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: a systematic review and meta‐analysis of randomized controlled trials

“…Of the 26 articles which were full text screened, a total of 11 articles did not meet the criteria of inclusion either because the independent effects of probiotics on outcomes were not possible to estimate (23)(24)(25)(26)(27)(28)(29)(30), the probiotic species were not defined (31) or the patients had undergone gastric bypass (32) or lacked sufficient information on the outcomes of interest (33). Finally, 15 articles were included in the systematic review and meta-analysis (34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48).…”

Metabolic role of lactobacilli in weight modification in humans and animals

“…These compounds improve the ability to compete against other 155 gastrointestinal pathogens and restore intestinal microbiota balance. However, the use of 160 Alteration of microbiota composition appears to have a direct effect on the host metabolism 161 [9]. Bacteria living in the gastrointestinal tract secrete enzymes which digest substrates not 162 digested by the host in the colon and participate in the degradation of lipids and sugars in the 163 duodenum and jejunum.…”

Changes in weight and body fat after use of tetracycline and Lactobacillus gasseri in rats

“…Studies of L. gasseri in humans have shown decreases in abdominal adiposity, body weight, and waist and hip circumferences after oral use of probiotics (Kadooka et al, 2010;Jung et al, 2013). Several studies show that the use of this microorganism in rats decreased visceral fat by enhancing lipid excretion (Yonejima, Ushida, Mori, 2013), reduced adipocyte size (Sato et al, 2008;Hamad et al, 2009), and reduced body weight (Kang Yun, Park, 2010;Kang et al, 2013).…”